Pharmacological therapies for Liposarcoma

Research output: Contribution to journalReview article

6 Citations (Scopus)

Abstract

Introduction: Liposarcoma (LS) is one of the most common adult soft tissue sarcomas (STS). For metastatic disease, systemic treatment options were historically represented by standard cytotoxic chemotherapy. More recently, innovative therapies have been introduced and they are currently part of the therapeutic armamentarium, positively impacting disease control and patients’ quality of life. Moreover, in the last decade, a better understanding of the molecular characteristics of each STS subtype allowed to detect new potential targets and develop novel, biology-driven compounds at different stages of testing. Areas covered: This review is focused on LS, retracing their pharmacological management, starting with a summary of results achieved with standard chemotherapy, then moving to a deeper analysis on data obtained with new, approved therapies and finally reporting an update on ongoing clinical trials, thus providing an overview on the current scenario and outlining how it might evolve in the coming years. Expert commentary: Important strides have been made in the knowledge and treatment of LS. Peculiar molecular features and fundamental signalling pathways represent nowadays druggable targets for novel therapies. However, predictive biomarkers still need to be identified in order to better select the target population, to possibly test combinations of drugs, with the ultimate goal of improving outcomes.

Original languageEnglish
Pages (from-to)361-377
Number of pages17
JournalExpert Review of Clinical Pharmacology
Volume10
Issue number4
DOIs
Publication statusPublished - Apr 3 2017

Fingerprint

Liposarcoma
Pharmacology
Sarcoma
Therapeutics
Drug Therapy
Investigational Therapies
Health Services Needs and Demand
Drug Combinations
Biomarkers
Quality of Life
Clinical Trials

Keywords

  • CDK4
  • chemotherapy
  • clinical trials
  • eribulin
  • MDM2
  • myxoid liposarcoma
  • pleomorphic liposarcoma
  • Sarcoma
  • trabectedin
  • WDLS/DDLS
  • well-differentiated/dedifferentiated liposarcoma

ASJC Scopus subject areas

  • Pharmacology, Toxicology and Pharmaceutics(all)
  • Pharmacology (medical)

Cite this

Pharmacological therapies for Liposarcoma. / Saponara, Maristella; Stacchiotti, Silvia; Gronchi, Alessandro.

In: Expert Review of Clinical Pharmacology, Vol. 10, No. 4, 03.04.2017, p. 361-377.

Research output: Contribution to journalReview article

@article{97f52101b1814642b4d55d8a4ffbe3d9,
title = "Pharmacological therapies for Liposarcoma",
abstract = "Introduction: Liposarcoma (LS) is one of the most common adult soft tissue sarcomas (STS). For metastatic disease, systemic treatment options were historically represented by standard cytotoxic chemotherapy. More recently, innovative therapies have been introduced and they are currently part of the therapeutic armamentarium, positively impacting disease control and patients’ quality of life. Moreover, in the last decade, a better understanding of the molecular characteristics of each STS subtype allowed to detect new potential targets and develop novel, biology-driven compounds at different stages of testing. Areas covered: This review is focused on LS, retracing their pharmacological management, starting with a summary of results achieved with standard chemotherapy, then moving to a deeper analysis on data obtained with new, approved therapies and finally reporting an update on ongoing clinical trials, thus providing an overview on the current scenario and outlining how it might evolve in the coming years. Expert commentary: Important strides have been made in the knowledge and treatment of LS. Peculiar molecular features and fundamental signalling pathways represent nowadays druggable targets for novel therapies. However, predictive biomarkers still need to be identified in order to better select the target population, to possibly test combinations of drugs, with the ultimate goal of improving outcomes.",
keywords = "CDK4, chemotherapy, clinical trials, eribulin, MDM2, myxoid liposarcoma, pleomorphic liposarcoma, Sarcoma, trabectedin, WDLS/DDLS, well-differentiated/dedifferentiated liposarcoma",
author = "Maristella Saponara and Silvia Stacchiotti and Alessandro Gronchi",
year = "2017",
month = "4",
day = "3",
doi = "10.1080/17512433.2017.1289086",
language = "English",
volume = "10",
pages = "361--377",
journal = "Expert Review of Clinical Pharmacology",
issn = "1751-2433",
publisher = "ROUTLEDGE JOURNALS, TAYLOR FRANCIS LTD",
number = "4",

}

TY - JOUR

T1 - Pharmacological therapies for Liposarcoma

AU - Saponara, Maristella

AU - Stacchiotti, Silvia

AU - Gronchi, Alessandro

PY - 2017/4/3

Y1 - 2017/4/3

N2 - Introduction: Liposarcoma (LS) is one of the most common adult soft tissue sarcomas (STS). For metastatic disease, systemic treatment options were historically represented by standard cytotoxic chemotherapy. More recently, innovative therapies have been introduced and they are currently part of the therapeutic armamentarium, positively impacting disease control and patients’ quality of life. Moreover, in the last decade, a better understanding of the molecular characteristics of each STS subtype allowed to detect new potential targets and develop novel, biology-driven compounds at different stages of testing. Areas covered: This review is focused on LS, retracing their pharmacological management, starting with a summary of results achieved with standard chemotherapy, then moving to a deeper analysis on data obtained with new, approved therapies and finally reporting an update on ongoing clinical trials, thus providing an overview on the current scenario and outlining how it might evolve in the coming years. Expert commentary: Important strides have been made in the knowledge and treatment of LS. Peculiar molecular features and fundamental signalling pathways represent nowadays druggable targets for novel therapies. However, predictive biomarkers still need to be identified in order to better select the target population, to possibly test combinations of drugs, with the ultimate goal of improving outcomes.

AB - Introduction: Liposarcoma (LS) is one of the most common adult soft tissue sarcomas (STS). For metastatic disease, systemic treatment options were historically represented by standard cytotoxic chemotherapy. More recently, innovative therapies have been introduced and they are currently part of the therapeutic armamentarium, positively impacting disease control and patients’ quality of life. Moreover, in the last decade, a better understanding of the molecular characteristics of each STS subtype allowed to detect new potential targets and develop novel, biology-driven compounds at different stages of testing. Areas covered: This review is focused on LS, retracing their pharmacological management, starting with a summary of results achieved with standard chemotherapy, then moving to a deeper analysis on data obtained with new, approved therapies and finally reporting an update on ongoing clinical trials, thus providing an overview on the current scenario and outlining how it might evolve in the coming years. Expert commentary: Important strides have been made in the knowledge and treatment of LS. Peculiar molecular features and fundamental signalling pathways represent nowadays druggable targets for novel therapies. However, predictive biomarkers still need to be identified in order to better select the target population, to possibly test combinations of drugs, with the ultimate goal of improving outcomes.

KW - CDK4

KW - chemotherapy

KW - clinical trials

KW - eribulin

KW - MDM2

KW - myxoid liposarcoma

KW - pleomorphic liposarcoma

KW - Sarcoma

KW - trabectedin

KW - WDLS/DDLS

KW - well-differentiated/dedifferentiated liposarcoma

UR - http://www.scopus.com/inward/record.url?scp=85015906469&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85015906469&partnerID=8YFLogxK

U2 - 10.1080/17512433.2017.1289086

DO - 10.1080/17512433.2017.1289086

M3 - Review article

C2 - 28135854

AN - SCOPUS:85015906469

VL - 10

SP - 361

EP - 377

JO - Expert Review of Clinical Pharmacology

JF - Expert Review of Clinical Pharmacology

SN - 1751-2433

IS - 4

ER -